More than 45 Delegates from the New Zealand Biotechnology Industry Highlight New Zealand Innovation and Global Connectedness at BIO 2005.PHILADELPHIA -- Over 150 Years of Life Sciences R&D Has Produced a Rapidly Growing Biotech Industry Addressed to Health and Wellness, Industrial Biotech, Agriculture, Forestry and More More than 150 years of life sciences research and technological innovation, combined with strong global partnerships, and a public-private collaborative approach to business have given New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. one of the world's fastest growing biotechnology industries. Today New Zealand biotechnology applications range beyond agriculture to add medicine, human health, wellness and performance, industrial biotechnology The references in this article would be clearer with a different and/or consistent style of citation, footnoting or external linking. Industrial biotechnology (known mainly in Europe as white biotechnology , forestry, biosecurity, and environmental applications. To promote awareness of New Zealand's growing global presence in biotechnology, the Honorable Pete Hodgson Peter Colin Hodgson (1950 - ) is a New Zealand politician. He is a member of the Labour Party. Hodgson was born in Whangarei, and received a Bachelor's degree in veterinary science from Massey University. , New Zealand Minister of Commerce and ex-Minister of Research, Science and Technology will lead a delegation of 47 companies and organizations to the BIO 2005 conference, taking place in Philadelphia, PA from June 19 - 22. Through its internationally oriented biotechnology industry and its presence at BIO 2005, New Zealand is reaching out to partner with leading U.S. and international research institutions and universities, companies, and state agencies. New Zealand Pavilion The New Zealand Government's economic development agency New Zealand Trade and Enterprise (NZTE NZTE New Zealand Trade and Enterprise ) will host a pavilion in the BIO 2005 Exhibition Hall. The pavilion will showcase a variety of New Zealand research initiatives and companies in the areas of human medicine, health and wellness, agricultural biotechnology, industrial biotechnology and support organizations. The pavilion will include a meeting area for networking and one-on-one meetings during the conference. NZTE will co-host with the Australian Pavilion a special exhibit hall event on Tuesday June 21, 2:00 - 4:00 pm, featuring fine wines from New Zealand and Australia. The New Zealand Pavilion is located in Hall C, Stands 749-856. New Zealand Country Seminar On Sunday June 19, International Day presenters for New Zealand will include Minister Hodgson, along with Chris Boalch, Director of Biotechnology, NZTE; Richard Furneux, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of GlycoSyn, an Industrial Research Ltd company focused on glycobiology; Larry Ellingson, CEO of Protemix USA, a New Zealand founded biopharmaceutical company; and Howard Moore, Executive Director of the recently founded venture firm, BioPacificVentures. Together they will provide an overview of the New Zealand biotech industry and business environment, including government initiatives planned to grow the industry, as well as the New Zealand industry's expanding international linkages. The New Zealand Minister of Commerce, Hon. Pete Hodgson, said, "Much of New Zealand's wealth has been built on a proven ability to add value to natural resources by applying biological knowledge. Now unique approaches to biotechnology pioneered in New Zealand are set to have a major impact on the way we all deal with health and environmental issues. "The New Zealand biotech sector has firm backing from the New Zealand Government which recognises its importance to the economy. It is working with the New Zealand biotechnology community to implement a detailed strategy to put in place the necessary infrastructure to promote success on a global scale." New Zealand Companies This is a list of major companies based in New Zealand. For convenience, the word "Limited", which every company registered or reregistered under the Companies Act 1993 (with one historic exception) must have at the end of its name, is reduced to the common and universally at BIO2005 Representatives of some of New Zealand's leading biotechnology companies, as well as scientists from cutting edge research programs at the country's Crown Research Institutes and Universities, will represent the nation's outstanding capabilities and global research at BIO2005. Just a few of the New Zealand companies represented at BIO include: --Proacta and Protemix are two companies that illustrate well the global connectedness of New Zealand biotechnology. Taking advantage of New Zealand innovation, scientific know-how and low cost of research, these two companies are among those who have expanded operations to the United States for access to larger patient populations and markets. Proacta is developing treatments for cancer that take advantage of the oxygen-poor environment in tumors. Protemix is engaged in the development of a novel treatment to repair heart damage in patients with diabetes, as well as other therapies for cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , diabetes and other metabolic conditions. --Lactopharma and Ovita are two companies whose research demonstrates New Zealand's ability to mine leading agricultural research for new human therapeutic applications. Lactopharma is developing applications of lactoferrin lactoferrin (lak´tōfer´in), n an iron-binding protein found in the specific granules of neutrophils where it apparently exerts an antimicrobial activity by withholding iron from ingested bacteria and fungi. , a milk-derived protein with both anti-inflammatory properties and the ability to promote bone formation and inhibit bone absorption. Ovita's research on muscle development and twinning in sheep offers opportunities for development new treatments against muscle wasting and to aid fertility in humans. --Pacific Edge Biotechnology Ltd, a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company with a strategic focus on "human health and wellness" combines state-of-the-art molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and micro array technology with world-class tissue banks and clinical data. These resources, combined with proprietary analytical software, enable the company to identify unique gene signatures of disease. --IRL - With a focus on creating new technologies, Industrial Research Ltd (IRL 1. (jargon, chat) IRL - In real life. Generally synonymous with f2f. 2. (language, robotics) IRL - Industrial Robot Language. ) draws from New Zealand science & technology platforms to create globally competitive products for customers worldwide. This focus includes a core emphasis within biotechnology. For example, one of IRL's key business units, GlycoSyn, is drawing from world-class expertise in carbohydrate chemistry to collaborate with Albert Einstein College of Medicine
The Albert Einstein College of Medicine (AECOM) is a graduate school of Yeshiva University. It is a private medical school located in the Jack and Pearl Resnick Campus of Yeshiva University in the Morris Park in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . This partnership has enabled them to produce novel treatments for cancer and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause that have led to further clinical development with companies in the United States and Australia. A separate spin-out company from Industrial Research, IRL Biopharm, manufactures many of the potent molecules used as "warheads" in anticancer antibodies under development by a major US biotech company. --Neuren Pharmaceuticals is a biopharmaceutical company whose product pipeline is applicable to two of the world's largest and fastest growing therapeutic markets: neuroprotection and metabolism. The company has many U.S. and other global collaborations, including one with Walter Reed Army Institute of Research This article is about the U.S. Army medical research institute (not the hospital). Otherwise, see Walter Reed (disambiguation). The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. focused on neuroprotectant treatments and traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain . For more information on New Zealand and its biotechnology industry, as well as its participation in BIO 2005, please visit www.nzte.govt.nz/bio2005. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion